Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection

肠道菌群衍生的代谢产物可预防SARS-CoV-2感染

阅读:3
作者:Julia A Brown ,Katherine Z Sanidad ,Serena Lucotti ,Carolin M Lieber ,Robert M Cox ,Aparna Ananthanarayanan ,Srijani Basu ,Justin Chen ,Mengrou Shan ,Mohammed Amir ,Fabian Schmidt ,Yiska Weisblum ,Michele Cioffi ,Tingting Li ,Florencia Madorsky Rowdo ,M Laura Martin ,Chun-Jun Guo ,Costas Lyssiotis ,Brian T Layden ,Andrew J Dannenberg ,Paul D Bieniasz ,Benhur Lee ,Naohiro Inohara ,Irina Matei ,Richard K Plemper ,Melody Y Zeng

Abstract

The gut microbiome is intricately coupled with immune regulation and metabolism, but its role in Coronavirus Disease 2019 (COVID-19) is not fully understood. Severe and fatal COVID-19 is characterized by poor anti-viral immunity and hypercoagulation, particularly in males. Here, we define multiple pathways by which the gut microbiome protects mammalian hosts from SARS-CoV-2 intranasal infection, both locally and systemically, via production of short-chain fatty acids (SCFAs). SCFAs reduced viral burdens in the airways and intestines by downregulating the SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2), and enhancing adaptive immunity via GPR41 and 43 in male animals. We further identify a novel role for the gut microbiome in regulating systemic coagulation response by limiting megakaryocyte proliferation and platelet turnover via the Sh2b3-Mpl axis. Taken together, our findings have unraveled novel functions of SCFAs and fiber-fermenting gut bacteria to dampen viral entry and hypercoagulation and promote adaptive antiviral immunity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。